GO:0010614 negative regulation of cardiac muscle hypertrophy: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010614 describes any process that decreases the rate, frequency or extent of pathological enlargement of the heart due to increased size (not length) of individual cardiac muscle fibers, without cell division.
• This biological process is distinct from physiological hypertrophy, which is adaptive and reversible, whereas pathological hypertrophy is maladaptive and progresses to heart failure.
• Key negative regulators include ANGPTL8, USP28, MCU (via CaMKIIδB), ALDH2, Rbfox2, and clusterin, which act through diverse mechanisms such as antioxidant response, calcium handling, and alternative splicing [2,4,5,6,7,8].
• Dysregulation of negative regulators contributes to diabetic cardiomyopathy, pressure-overload heart failure, and ischemia-reperfusion injury [3,6,7].
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to validate causal roles of candidate genes in this process [2,4,5].
• Therapeutic targeting of negative regulators, such as A2AR-D2R dimerization or PDE10A, offers novel strategies to limit pathological cardiac remodeling.
Description
Cardiac hypertrophy is an adaptive response to increased workload, but sustained pathological hypertrophy leads to heart failure. The Gene Ontology term GO:0010614, negative regulation of cardiac muscle hypertrophy, encompasses any process that decreases the rate, frequency or extent of the enlargement or overgrowth of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division. This term is critical for understanding endogenous protective mechanisms that counteract maladaptive remodeling. Research has identified numerous negative regulators, including ANGPTL8, which attenuates pathological hypertrophy through autocrine/paracrine signaling, and USP28, which deubiquitinates TRIM21 to suppress antioxidant responses and promote hypertrophy. Other regulators such as MCU, ALDH2, Rbfox2, and clusterin modulate calcium handling, oxidative stress, and splicing [5,6,7,8]. Understanding these pathways is essential for developing targeted therapies for heart failure.
negative regulation of cardiac muscle hypertrophy At A Glance
| GO ID | GO:0010614 |
|---|---|
| GO term | negative regulation of cardiac muscle hypertrophy |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency or extent of cardiac muscle hypertrophy without cell division |
| Related process | Regulation of cardiac muscle hypertrophy (GO:0010613) |
| Opposite process | Positive regulation of cardiac muscle hypertrophy (GO:0010615) |
| Disease relevance | Heart failure, diabetic cardiomyopathy, pressure-overload hypertrophy |
| Key regulators | ANGPTL8, USP28, MCU, ALDH2, Rbfox2, clusterin |
What Is GO:0010614?
GO:0010614 is a biological process defined as any process that decreases the rate, frequency or extent of the enlargement or overgrowth of all or part of the heart due to an increase in size (not length) of individual cardiac muscle fibers, without cell division. In simpler terms, it refers to the body's natural mechanisms that put the brakes on pathological heart enlargement at the cellular level, preventing the heart from becoming abnormally thick and dysfunctional.
Why Is negative regulation of cardiac muscle hypertrophy Important in Cell Biology?
GO:0010614 is crucial because pathological cardiac hypertrophy is a leading cause of heart failure, arrhythmias, and sudden death. Identifying negative regulators provides potential therapeutic targets to halt or reverse maladaptive remodeling. For example, ANGPTL8 overexpression attenuates hypertrophy, while its knockdown exacerbates it. Similarly, USP28 deficiency protects against hypertrophy by enhancing antioxidant responses. Understanding these processes at the molecular level can guide the development of gene therapies or small molecules that boost endogenous protective pathways.
• Pathological cardiac hypertrophy is an independent risk factor for heart failure and mortality.
• Negative regulators like ANGPTL8 offer protective effects against pressure overload-induced hypertrophy.
• USP28 promotes hypertrophy by deubiquitinating TRIM21 and suppressing antioxidant response, making it a therapeutic target.
• MCU elevation by CaMKIIδB limits pathological remodeling, highlighting calcium signaling in negative regulation.
• ALDH2 activation by SGLT2 inhibitors improves cardiac remodeling, linking metabolism to hypertrophy suppression.
• Dysregulated Rbfox2 splicing of CaV1.2 contributes to diabetic cardiac hypertrophy, showing the role of RNA-binding proteins.
• Clusterin regulation after transverse aortic constriction suggests a role in negative regulation of hypertrophy.
• A2AR-D2R dimerization and PDE10A signaling modulate hypertrophy, offering new drug targets.
• CRISPR-based models are essential to dissect causal roles of these regulators in vivo and in vitro [2,4,5].
• The term helps standardize annotation of genes and pathways in cardiac hypertrophy research.
What Happens During negative regulation of cardiac muscle hypertrophy?
Initiation of negative regulatory signals
In simple terms: The heart senses stress and activates protective signals to stop excessive growth.
Negative regulation begins when cardiomyocytes detect stressors such as pressure overload or neurohormonal activation. This triggers signaling cascades that oppose hypertrophic growth. For instance, ANGPTL8 is secreted and acts as a negative regulator in pathological cardiac hypertrophy. Similarly, A2AR-D2R dimerization and D2R-biased signaling mediate PDE10A-dependent suppression of hypertrophy. These initial signals set the stage for downstream protective mechanisms.
Suppression of pro-hypertrophic transcription and translation
In simple terms: The cell blocks the production of proteins that make heart cells grow bigger.
Once negative regulatory signals are engaged, they inhibit transcription factors such as NFAT, MEF2, and GATA4 that drive hypertrophic gene expression. For example, USP28 negatively regulates antioxidant response by deubiquitinating TRIM21, thereby promoting hypertrophy; its inhibition enhances antioxidant genes and suppresses hypertrophy. MCU elevation by CaMKIIδB limits pathological remodeling by modulating mitochondrial calcium and reducing oxidative stress. These events collectively reduce the synthesis of structural proteins and fetal gene reprogramming.
Modulation of calcium handling and splicing
In simple terms: The cell fine-tunes calcium signals and corrects faulty RNA splicing to prevent hypertrophy.
Calcium handling is central to cardiac hypertrophy. MCU (mitochondrial calcium uniporter) elevation by CaMKIIδB limits pathological remodeling by maintaining mitochondrial calcium homeostasis. Dysregulated Rbfox2 produces aberrant splicing of CaV1.2 calcium channel in diabetes-induced cardiac hypertrophy, and restoring Rbfox2 function suppresses hypertrophy. These mechanisms ensure proper excitation-contraction coupling and prevent maladaptive remodeling.
Metabolic and antioxidant regulation
In simple terms: The cell boosts its defense against oxidative stress and improves energy use to stop hypertrophy.
ALDH2 mediates the effects of SGLT2 inhibitors on improving cardiac remodeling, linking metabolic regulation to hypertrophy suppression. Clusterin is regulated in the heart and plasma after transverse aortic constriction, suggesting a role in negative regulation. USP28 negatively regulates antioxidant response, and its inhibition protects against hypertrophy. These pathways reduce oxidative damage and metabolic stress, thereby limiting hypertrophic growth.
Integration and long-term remodeling
In simple terms: The heart integrates multiple protective signals to maintain normal size and function.
The cumulative effect of these negative regulatory mechanisms is the suppression of pathological hypertrophy and preservation of cardiac function. For example, ANGPTL8 overexpression attenuates hypertrophy and improves cardiac function in pressure-overload models. A2AR-D2R dimerization and PDE10A signaling provide a brake on hypertrophic growth. When these pathways fail, maladaptive remodeling progresses to heart failure.
Key Genes Involved in GO:0010614 negative regulation of cardiac muscle hypertrophy
The following genes and proteins have been experimentally implicated in the negative regulation of cardiac muscle hypertrophy, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ANGPTL8 | Secreted negative regulator of pathological cardiac hypertrophy | Overexpression attenuates hypertrophy; knockdown exacerbates |
| USP28 | Deubiquitinates TRIM21, suppresses antioxidant response, promotes hypertrophy | Inhibition protects against hypertrophy |
| MCU | Mitochondrial calcium uniporter; elevated by CaMKIIδB to limit remodeling | Modulates calcium and oxidative stress |
| ALDH2 | Mitochondrial aldehyde dehydrogenase; mediates SGLT2i effects | Improves cardiac remodeling |
| Rbfox2 | RNA-binding protein regulating alternative splicing of CaV1.2 | Dysregulation causes diabetic hypertrophy |
| Clusterin | Secreted chaperone; regulated after transverse aortic constriction | Potential negative regulator |
| PDE10A | Phosphodiesterase; mediates D2R-biased signaling | Suppresses hypertrophy via cAMP/cGMP |
| CaMKIIδB | Calcium/calmodulin-dependent kinase; regulates MCU expression | Limits pathological remodeling |
| TRIM21 | E3 ubiquitin ligase; target of USP28 | Promotes hypertrophy when deubiquitinated |
| A2AR | Adenosine A2A receptor; forms dimer with D2R | Modulates hypertrophy signaling |
| D2R | Dopamine D2 receptor; biased signaling | Suppresses hypertrophy via PDE10A |
| CaV1.2 | L-type calcium channel; spliced by Rbfox2 | Aberrant splicing contributes to hypertrophy |
| SGLT2 | Sodium-glucose cotransporter 2; target of inhibitors | Inhibitors improve remodeling via ALDH2 |
| NFAT | Transcription factor driving hypertrophic gene program | Suppressed by negative regulators |
| MEF2 | Transcription factor promoting hypertrophy | Inhibited by negative regulators |
| GATA4 | Transcription factor involved in hypertrophy | Target of negative regulation |
How Is negative regulation of cardiac muscle hypertrophy Regulated?
The negative regulation of cardiac muscle hypertrophy is controlled by a complex network of signaling pathways. Key regulators include the ANGPTL8 pathway, which acts as a secreted negative regulator, and the USP28-TRIM21 axis, which modulates antioxidant response. Calcium signaling through MCU and CaMKIIδB limits remodeling. Metabolic regulators such as ALDH2 and SGLT2 inhibitors improve cardiac remodeling. RNA-binding protein Rbfox2 controls splicing of CaV1.2. Additionally, A2AR-D2R dimerization and PDE10A signaling provide a brake on hypertrophy. These pathways are interconnected and often converge on transcription factors like NFAT and MEF2.
negative regulation of cardiac muscle hypertrophy and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ANGPTL8 | Pathological cardiac hypertrophy | Overexpression and knockout mouse models |
| USP28 | Hypertrophy and oxidative stress | Cardiomyocyte-specific knockout |
| Rbfox2 | Diabetic cardiomyopathy | Knockout and rescue with splicing correction |
| ALDH2 | Cardiac remodeling in diabetes | Knockout and SGLT2i treatment |
| MCU | Pressure-overload remodeling | Cardiomyocyte-specific overexpression |
Heart failure and pathological hypertrophy
Pathological cardiac hypertrophy is a major precursor to heart failure. Negative regulators such as ANGPTL8 and USP28 play critical roles in limiting hypertrophy. ANGPTL8 overexpression attenuates pressure overload-induced hypertrophy and improves cardiac function. USP28 inhibition enhances antioxidant response and protects against hypertrophy. Loss of these protective mechanisms contributes to maladaptive remodeling and progression to heart failure.
Diabetic cardiomyopathy
Diabetes-induced cardiac hypertrophy is associated with dysregulated Rbfox2, which produces aberrant splicing of CaV1.2 calcium channel. Restoring Rbfox2 function or correcting splicing suppresses hypertrophy. ALDH2 mediates the beneficial effects of SGLT2 inhibitors on cardiac remodeling in diabetes. These findings highlight the importance of negative regulation in diabetic cardiomyopathy.
Ischemia-reperfusion injury and oxidative stress
Oxidative stress contributes to cardiac hypertrophy and injury. USP28 negatively regulates antioxidant response, and its inhibition reduces hypertrophy by upregulating antioxidant genes. MCU elevation by CaMKIIδB limits pathological remodeling by maintaining mitochondrial calcium homeostasis and reducing oxidative stress. Clusterin, a stress-induced chaperone, is regulated after transverse aortic constriction and may protect against hypertrophy.
From negative regulation of cardiac muscle hypertrophy-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ANGPTL8 negatively regulate hypertrophy? | Cardiomyocyte-specific overexpression and knockout mice |
| What is the role of USP28 in antioxidant response? | USP28 knockout mice and cardiomyocytes |
| How does MCU elevation limit remodeling? | MCU overexpression in cardiomyocytes |
| Does ALDH2 mediate SGLT2i effects? | ALDH2 knockout mice treated with SGLT2i |
| Is Rbfox2 splicing critical in diabetic hypertrophy? | Rbfox2 knockout and rescue with CaV1.2 splice variants |
| Does clusterin regulate hypertrophy? | Clusterin knockout mice after TAC |
How to Study the negative regulation of cardiac muscle hypertrophy Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression changes | Identify hypertrophic gene programs |
| Ribo-seq | Translational efficiency | Discover translationally regulated genes |
| Proteomics | Protein abundance and modifications | Uncover signaling changes |
| Ubiquitinome | Ubiquitination sites | Identify USP28 substrates |
| Echocardiography | Cardiac structure and function | Assess hypertrophy in vivo |
| Histology | Cardiomyocyte size | Quantify hypertrophy |
| Calcium imaging | Intracellular calcium dynamics | Study MCU and CaMKIIδB |
| CRISPR screen | Gene function at scale | Discover novel regulators |
Transcriptomic and splicing analysis
RNA-seq and Ribo-seq can identify changes in gene expression and translation underlying negative regulation. For example, Rbfox2-dependent splicing of CaV1.2 was discovered using RNA-seq. These methods help uncover novel regulators and their downstream targets.
Proteomic and ubiquitinome profiling
Mass spectrometry-based proteomics and ubiquitinome analysis can reveal post-translational modifications. USP28 deubiquitinates TRIM21, and ubiquitinome profiling can identify substrates. These approaches are essential for understanding signaling mechanisms.
Imaging and functional assays
Echocardiography, histology, and immunofluorescence measure cardiac hypertrophy and function. For instance, ANGPTL8 overexpression was shown to reduce hypertrophy by echocardiography. Calcium imaging and mitochondrial function assays assess MCU and CaMKIIδB roles.
CRISPR screening and bioinformatics
Genome-wide CRISPR screens can identify negative regulators of hypertrophy. Bioinformatics integration of transcriptomic and proteomic data can pinpoint pathways. These methods accelerate target discovery.
How CRISPR Can Be Used to Study GO:0010614 negative regulation of cardiac muscle hypertrophy
Knockout
CRISPR knockout of candidate negative regulators such as ANGPTL8 or USP28 in cardiomyocytes or mouse models can confirm their role in hypertrophy. For example, USP28 knockout enhances antioxidant response and protects against hypertrophy. ANGPTL8 knockout exacerbates hypertrophy.
Point Mutation
Point mutations can dissect specific domains or phosphorylation sites. For instance, mutating the deubiquitinase domain of USP28 can reveal its catalytic role in hypertrophy. Similarly, point mutations in MCU can affect calcium transport.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of endogenous proteins. A knock-in of fluorescently tagged ANGPTL8 can monitor its secretion and localization. Knock-in of mutant CaV1.2 splice variants can test their role in hypertrophy.
Overexpression
Overexpression of negative regulators such as ANGPTL8 or ALDH2 can suppress hypertrophy. Transgenic mice overexpressing ANGPTL8 show reduced hypertrophy after pressure overload. Overexpression of ALDH2 mimics SGLT2i effects.
How EDITGENE Supports negative regulation of cardiac muscle hypertrophy Research
Researchers studying negative regulation of cardiac muscle hypertrophy-related genes often need to determine whether a candidate gene is causally involved in suppressing or promoting hypertrophic growth. This requires precise genetic models to manipulate gene function in cardiomyocytes and assess downstream effects on cardiac structure and function.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac muscle hypertrophy research.
Frequently Asked Questions About negative regulation of cardiac muscle hypertrophy
What is GO:0010614?
GO:0010614 is a Gene Ontology term for negative regulation of cardiac muscle hypertrophy, describing any process that decreases the rate, frequency or extent of heart enlargement due to increased size of cardiac muscle fibers without cell division.
What genes are involved in negative regulation of cardiac muscle hypertrophy?
Key genes include ANGPTL8, USP28, MCU, ALDH2, Rbfox2, clusterin, PDE10A, and CaMKIIδB, among others [2,3,4,5,6,7,8].
How does ANGPTL8 regulate cardiac hypertrophy?
ANGPTL8 acts as a secreted negative regulator; its overexpression attenuates pathological hypertrophy, while knockdown exacerbates it.
What is the role of USP28 in cardiac hypertrophy?
USP28 deubiquitinates TRIM21, suppressing antioxidant response and promoting hypertrophy; its inhibition protects against hypertrophy.
How does MCU affect pathological cardiac remodeling?
Elevated MCU expression by CaMKIIδB limits pathological remodeling by maintaining mitochondrial calcium homeostasis.
What is the link between ALDH2 and SGLT2 inhibitors in cardiac remodeling?
ALDH2 mediates the beneficial effects of SGLT2 inhibitors on improving cardiac remodeling in diabetes.
How does Rbfox2 contribute to diabetic cardiac hypertrophy?
Dysregulated Rbfox2 produces aberrant splicing of CaV1.2 calcium channel, contributing to hypertrophy; restoring Rbfox2 suppresses it.
What is the significance of clusterin in cardiac hypertrophy?
Clusterin is regulated in the heart after transverse aortic constriction, suggesting a role in negative regulation of hypertrophy.
How can CRISPR be used to study negative regulation of cardiac hypertrophy?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional validation of candidate genes in cardiomyocytes and mouse hearts [2,4,5].
What research methods are used to study GO:0010614?
Common methods include RNA-seq, Ribo-seq, proteomics, ubiquitinome profiling, echocardiography, histology, and calcium imaging [1,2,5].
Conclusion
GO:0010614, negative regulation of cardiac muscle hypertrophy, is a critical biological process that counteracts pathological heart enlargement. Research has identified numerous negative regulators, including ANGPTL8, USP28, MCU, ALDH2, Rbfox2, and clusterin, which act through diverse mechanisms such as antioxidant response, calcium handling, and alternative splicing [2,4,5,6,7,8]. Understanding these pathways offers promising therapeutic targets for heart failure and diabetic cardiomyopathy. CRISPR-based models and multi-omics approaches are essential to dissect these mechanisms and translate findings into clinical applications.
References
- 1. Nakamura M et al.. 2018. Mechanisms of physiological and pathological cardiac hypertrophy.. Nat Rev Cardiol 15(7):387-407 PMID: 29674714
- 2. Han J et al.. 2024. Cardiomyocyte-derived USP28 negatively regulates antioxidant response and promotes cardiac hypertrophy via deubiquitinating TRIM21.. Theranostics 14(16):6236-6248 PMID: 39431010
- 3. Chen S et al.. 2025. Role of A(2A)R-D2R Dimerization and D(2)R-Biased Signaling in PDE10A-Mediated Cardiac Hypertrophy.. Circulation 152(19):1371-1392 PMID: 40970278
- 4. Hu L et al.. 2022. ANGPTL8 is a negative regulator in pathological cardiac hypertrophy.. Cell Death Dis 13(7):621 PMID: 35851270
- 5. Wang P et al.. 2022. Elevated MCU Expression by CaMKIIδB Limits Pathological Cardiac Remodeling.. Circulation 145(14):1067-1083 PMID: 35167328
- 6. Liu H et al.. 2024. ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling.. Cardiovasc Diabetol 23(1):380 PMID: 39462342
- 7. Li P et al.. 2023. Dysregulated Rbfox2 produces aberrant splicing of Ca(V)1.2 calcium channel in diabetes-induced cardiac hypertrophy.. Cardiovasc Diabetol 22(1):168 PMID: 37415128
- 8. Turkieh A et al.. 2024. Regulation of Clusterin in the Heart and Plasma of Mice After Transverse Aortic Constriction.. J Cell Mol Med 28(23):e70290 PMID: 39671261
